Immatics N.V. IMTX
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -31.43%
- 1 year
- -30.90%
- Open
- 7.26
- Prev close
- 7.31
- Mkt cap
- 1.10B
- Vol
- 1.72M
- Avg vol
- 810.06K
- EPS
- -1.87
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.81
- High
- 7.40
- Forward P/E
- -3.57
- Beta
- 1.36
- Short ratio
- 4.03
- Inst. own
- 66.81%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 17, 2026
- 50-d avg
- 8.28
- 200-d avg
- 9.60
- 1y target
- 16.97
News
-
6 days ago benzinga.com
Reported Saturday, Immatics Reports IMA203CD8 Cell Therapy 51% ORR, 41% cORR Across Multiple Solid Tumors With Manageable Safety; IMA402 Bispecific Shows 32% cORR In PRAME-High Melanoma, Favorable Safety Profile
IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profileIMA402 achieved a cORR of 32%, 12.5 months median DOR and…
1 week ago globenewswire.com
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Houston, Texas and Tuebingen, Germany, October 24, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage…
2 weeks ago benzinga.com
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
-
2 weeks ago benzinga.com
Stifel Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $15
Stifel analyst Laura Prendergast initiates coverage on Immatics (NASDAQ:IMTX) with a Buy rating and announces Price Target of $15.
-
3 weeks ago defenseworld.net
Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrast
Kyntra Bio (NASDAQ: KYNB - Get Free Report) and Immatics (NASDAQ: IMTX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two…
3 weeks ago defenseworld.net
Immatics (NASDAQ:IMTX) Reaches New 1-Year Low – Here’s Why
Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Friday. The stock traded as low as $7.02 and last traded at $7.37, with a volume of…
1 month ago defenseworld.net
Immatics (NASDAQ:IMTX) Sees Strong Trading Volume – Still a Buy?
Immatics N.V. (NASDAQ: IMTX - Get Free Report) shares saw unusually-strong trading volume on Wednesday. 434,954 shares changed hands during trading, a decline of 11% from the previous session's…
2 months ago seekingalpha.com
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma
Immatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination and pivotal trial dependency. IMTX's investment thesis centers on anzu-cel [IMA203], a…
2 months ago benzinga.com
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
-
2 months ago benzinga.com
Immatics Announces $150M Underwritten Offering Of Ordinary Shares And Pre-Funded Warrants
Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced
2 months ago globenewswire.com
Immatics Announces $150 Million Underwritten Offering
Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage…
-
2 months ago benzinga.com
Immatics Q2 EPS $(0.53) Misses $(0.43) Estimate, Sales $10.630M Miss $14.590M Estimate
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.43) by 23.26 percent. This is a 19.7 percent increase over losses of $(0.66)…
2 months ago globenewswire.com
Immatics Announces Second Quarter 2026 Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, August 18, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage…
3 months ago defenseworld.net
Analysts Set Immatics N.V. (NASDAQ:IMTX) Target Price at $20.80
Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the company,…
3 months ago globenewswire.com
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage…
4 months ago seekingalpha.com
Immatics: PRAME Is Becoming More Than A Single-Asset Story
Immatics is evolving into a PRAME-focused oncology platform with three monetization paths, not just a single-asset cell therapy play. IMTX's lead asset, anzu-cel, is in Phase 3 for advanced melanoma,…
-
5 months ago benzinga.com
Immatics Announces Extended Data From Phaseb Clinicla Trial Evaluating Anzu-Cel PRAME TCR T-Cell Therapy In Heavily Pretreated Patients With Advanced Melanoma At ASCO Annual Meeting
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and…
5 months ago globenewswire.com
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and…
5 months ago globenewswire.com
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck…
5 months ago globenewswire.com
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer…
5 months ago zacks.com
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics (IMTX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.35 per share a year ago.
-
5 months ago benzinga.com
Immatics Q1 EPS $(0.50) Misses $(0.42) Estimate, Sales $8.914M Miss $14.590M Estimate
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.42) by 19.05 percent. This is a 42.86 percent decrease over losses of $(0.35)…
5 months ago globenewswire.com
Immatics Announces First Quarter 2026 Financial Results and Business Update
SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company's first commercial launch planned in 2027 Multiple key…
5 months ago zacks.com
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
6 months ago globenewswire.com
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany, April 21, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage…
-
6 months ago benzinga.com
Immatics Announces Its Abstract Regarding Pediatric Participant Treatment With PRAME-Directed Cell Therapy Using Its PRAME T-Cell Receptor Accpected For Poster Presentation At American Association For Cancer Research Annual Meeting 2026
Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today…
8 months ago benzinga.com
Immatics Earnings Report: Q4 Overview
Immatics Earnings Report: Q4 Overview
-
8 months ago benzinga.com
Immatics Q4 EPS $(0.34) Beats $(0.48) Estimate, Sales $23.005M Beat $12.180M Estimate
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.48) by 29.17 percent. This is a 170.83 percent decrease over earnings of $0.48…
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1 year ago benzinga.com
Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
-
4 years ago benzinga.com
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
-
4 years ago benzinga.com
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 90 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 671 companies achieved new lows for the year.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 368 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 348 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 313 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 88 companies set new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
Wednesday morning saw 162 companies set new 52-week highs.
-
6 years ago benzinga.com
Defiance NextGen SPAC IPO ETF Launches: What Investors Need To Know
An ETF based on special purpose acquisition companies that trades on a U.S. exchange is now available to investors for the first time.